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Abstract: Background: Within three to six months after delivery, 13%–19% of women suffer from
post-partum depression (PPD), understood as a dysfunctional adaptation to the postpartum condition
and motherhood. In the present cross-sectional study, we compared the hair steroid levels of women
12 weeks before and after delivery and with or without PPD. Method: The present study was a
cross-sectional study conducted twelve weeks after delivery. At that time, 48 women (mean age:
25.9 years) with PPD and 50 healthy controls (mean age: 25.2 years) completed questionnaires
on depressive symptoms. Further, at the same time point, 6 cm lengths of hair strands were
taken, providing samples of hair steroids 12 weeks before and 12 weeks after delivery in order to
analyze hair steroids (cortisol, cortisone, progesterone, testosterone, and dehydroepiandrosterone
(DHEA)). Results: Compared to those of women without PPD, hair steroid levels (cortisol,
cortisone, progesterone) were significantly lower in women with PPD both before and after delivery.
Lower prenatal cortisone and progesterone levels predicted higher depression scores 12 weeks after
delivery. Lower prenatal levels of cortisol and progesterone and higher levels of DHEA, and postnatal
lower levels of cortisol, cortisone, and progesterone, along with higher levels of DHEA predicted
PPD-status with an accuracy of 98%. Conclusions: PPD is associated with blunted hair cortisol,
cortisone, and progesterone secretions both pre- and postpartum. Such blunted steroid levels appear
to reflect a stress responsivity that is less adaptive to acute and transient stressors. It follows that
prenatally assessed low hair cortisol and progesterone levels, along with high DHEA levels, are reliable
biomarkers of post-partum depression 12 weeks after delivery.
Keywords: pre- and postnatal hair steroids; post-partum depression; cortisol; cortisone; testosterone;
progesterone; DHEA
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1. Introduction
It is estimated that a few days after delivery 40%–80% of mothers suffer from symptoms of
depression (“baby blues”). Furthermore, 13%–19% suffer from post-partum depression (PPD) in the
first six months following delivery [1–3]. Typically, women with PPD exhibit fewer positive emotions
and more negative emotions towards their child, and they are less responsive and sensitive to the
newborn’s behavior and interactional efforts [1–3]. Additionally, mothers with PPD display a sad
and depressed mood, a virtually complete loss of activity, fatigue, and loss of energy, feelings of
worthlessness and guilt, poor cognitive performance, severe sleep disturbance, and signs of suicidal
behavior [4]. Heron et al. [5] have suggested that symptoms of depression and anxiety before
pregnancy could predict the emergence of PPD. From the perspective of evolutionary psychology
and psychiatry [6–9] and bearing in mind humans’ ancestral environment, PPD could be seen as an
adaptive response: Withdrawing from social activities as a result of real or perceived lack of social
support and reducing ‘investment’ in the newborn both reduces social stress and prompts the mother’s
community to invest more effort and resources both in the newborn and the mother [6]. In contrast,
from a psychiatric point of view, PPD is regarded as a major depressive disorder, with the specifier of
onset four weeks after delivery [4], and, as such, must be treated following evidence-based algorithms.
To further support such algorithms, research on psychophysiological variables has been undertaken to
explain the emergence and maintenance of PPD [10–12].
Specifically, neuroendocrine changes are attracting growing interest in PPD research [13].
Research on the role of neuroendocrines (and particularly cortisol) in major depressive disorders [14] and
post-traumatic stress disorder [15] has indicated that an altered hypothalamus-pituitary-adrenocortical
axis activity (HPA AA) is associated with these affective disorders [16]. In the present study, we focused
on steroids (cortisol, cortisone, progesterone, testosterone and dehydroepiandrosterone or DHEA),
and we examined the relation of levels of these steroids with symptoms of depression (both antepartum
and postpartum). To this end, we analyzed steroids in hair strands, as hair strands are considered a
retrospective calendar and thus provide insight into changes in steroid secretion over time and as a
function of women’s long-term affective states. [10,17,18]. Furthermore, steroid concentrations in hair
are robust against short-term psychophysiological fluctuations, and hair strands are easy to collect,
transport, and preserve at room temperature [10,17,18]. In contrast, steroids in blood, urine or saliva
might reflect current physiological and psychological states, circadian rhythms of the time of the day of
sampling, and situational circumstances, such as food intake and subjectively perceived stress [19,20].
In the following sections, we provide a brief overview of studies on steroids during and after
pregnancy. Such steroids, and above all, cortisol, were mainly assessed in blood, saliva, and urine, and,
to a much lesser extent, in hair.
1.1. Plasma Cortisol in Healthy Pregnant Women
Focusing on plasma cortisol in healthy pregnant women, Jung et al. [21] found an increase
in free cortisol and corticosteroid-binding globulin (CBG) from the second to the third trimester.
These authors also briefly summarized previous publications and concluded that this rise in total
plasma cortisol in healthy pregnant women appears to be related to up-regulation of the maternal
hypothalamic-pituitary-adrenal axis in addition to elevated CBG. Furthermore, cortisol levels in the
last trimester may be as much as two to three times higher than in the first trimester. Specifically,
the up-regulation of HPA AA leads to an increase in total plasma cortisol. However, the parallel rise in
CBG levels buffers these increasing levels of cortisol. As a result, the increase in active and free cortisol
is less pronounced. This mechanism protects both mother and infant against detrimental exposure to
high cortisol levels. Thus, increases in plasma cortisol from the second to the third trimester reflect
physiological adaptations to pregnancy among healthy women.
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1.2. Salivary, Blood and Urine Cortisol in Pregnant Women with Major Depressive Disorders
Complementary to this, Tsubouchi et al. [11] observed lower antenatal salivary cortisol levels in
women suffering from major depressive disorders during the second and third trimester. Likewise,
Glynn et al. [22] found lower saliva cortisol levels in women with PPD, consistent with the
notion of hypocortisolism in such women. Hypocortisolism in women with PPD appears to be
neuro-endocrinologically closer to post-traumatic stress disorder (PTSD) than to MDD [15,16,23]. Thus,
we expected in the present study to find that participants with PPD would have lower hair cortisol
levels during their third trimester than would healthy mothers.
Focusing further on salivary and blood cortisol and PPD, Seth et al. [13] conducted a systematic
review of 47 studies focusing on cortisol levels and symptoms of PPD. Seth et al. [13] found that
methodological differences (sample size, assessment of symptoms of depression, methods of cortisol
sampling (saliva, blood), and assessment time after delivery) made it difficult to identify any clear-cut
pattern of results. Nevertheless, they concluded that hypercortisolemia appears to be associated with
transient depressive states, while the hypocortisolemia appears to be related to chronic PPD.
In contrast, in a systematic review of possible biomarkers of post-partum depression,
Serati et al. [24] found that the pattern of associations between HPA AA (with saliva and blood
cortisol levels as outcome variables) and PPD was unclear. However, Szpunar and Parry [25] concluded
in their systematic review that there was converging evidence of lower morning blood cortisol levels
in women with PPD than in healthy controls, while for other hormones, such as prolactin and thyroid
hormones, the pattern of results was less clear. Specifically, Szpunar and Parry [25] commented on two
studies by Field et al. [26,27], in which women with PPD had higher urinary cortisol levels during
the second, but not during the third, trimester, when compared to healthy controls, thus pointing to a
down-regulation of HPA AA 12 weeks before delivery. However, Field and colleagues were unable
to replicate these findings in a later study [28], indicating that contradictory findings can arise even
within the same research group.
Duthie and Reynolds [29] concluded from their systematic review that the experience of chronic
stressful life events during early pregnancy is associated with a blunted peaking of salivary cortisol
levels in the morning. The experience of positive life events reduces morning salivary cortisol levels,
while the experience of negative life events is not associated with morning salivary cortisol levels.
Duthie and Reynolds [29] concluded that different stressors appear to have differing effects on the
HPA AA among women during and after pregnancy.
Collectively, the pattern of results from cortisol concentrations in saliva, blood, and urine in
pregnant women with PPD does not seem to be fully consistent. Nevertheless, a hypercortisolemia was
mainly associated with transient symptoms of depression, while a hypocortisolemia was associated
with chronic symptoms of depression.
1.3. Hair Cortisol in Women with Post-Partum Depression
Research on hair steroids, and specifically cortisol, in women with PPD is inconclusive and
scarce, compared to studies on the HPA AA in women with PPD focusing on saliva, urine,
and blood cortisol [30,31]. This is surprising since hair cortisol concentrations provide a unique
objective biomarker for the analysis of endogenous cortisol levels for clinical diagnostics and
research [32]. Although Stalder et al. [19] cautioned that sex, age, hair washing frequency, hair treatment,
and contraceptive use could all modify hair cortisol levels, Braig et al. [18,33] claimed that hair cortisol
concentrations are robust across a broad range of confounding influences, such as gender, hair color,
age, or hair treatment.
Caparros-Gonzalez et al. [34] assessed 44 women postpartum at either low or high risk of
post-partum depression. Hair strands were taken 16 days after delivery; these hair strands reflected
the hair cortisol concentrations of the three trimesters of pregnancy. Caparros-Gonzalez et al. [34]
observed that hair cortisol concentrations increased continuously in women without symptoms of
PPD from the first to the third trimester. This pattern of increasing cortisol concentrations during
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pregnancy among healthy women was further confirmed by Duthie and Reynolds [29]. In contrast,
Caparros-Gonzalez et al. [34] showed that in women with symptoms of PPD, hair cortisol concentrations
were consistently and significantly higher than the concentrations for women without PPD. Furthermore,
a multiple regression analysis revealed that higher hair cortisol concentrations during the first trimester
predicted the risk of suffering from symptoms of PPD. An additional result was that higher hair cortisol
concentrations were associated with stronger symptoms of subjective pregnancy-specific stress and
stronger symptoms of depression and anxiety. Likewise, Kalra et al. [35] observed that, in a sample of
25 healthy women, higher hair cortisol concentrations during pregnancy were associated with higher
perceived stress.
In contrast to the results of Caparros-Gonzalez et al. [34], Braig et al. [33] were unable to find any
kind of association between hair cortisol concentrations and self-reported symptoms of chronic stress,
anxiety, or depression in a sample of 768 participants. To explain these null findings, Braig et al. [33]
argued that the completion of self-rating questionnaires about 1.5 days after delivery might have
biased recall from long-term memory.
Braig et al. [33] also reviewed previous studies and concluded that symptoms of anxiety and
depression might be associated with both a hypo- and hyperactivity of the HPA AA, as measured by
hair cortisol concentrations.
Orta et al. [36] assessed hair cortisol concentrations in 97 pregnant women, separately for all
three trimesters, and observed that higher scores for general anxiety and perceived stress were
associated with lower hair cortisol concentrations. Again, these results are a good match with findings
reported elsewhere [19,37]. Lower hair cortisol concentrations appeared to be associated with chronic
stress [38–40] and psychiatric disorders, such as generalized anxiety disorders [41,42] and PTSD [43–46].
To summarize, studies on hair cortisol during and after pregnancy are scarce and the pattern of
results appears inconsistent. Such inconsistent findings appear to reflect, above all, methodological
issues, such as the timing of psychological assessments and the lack of a thorough diagnosis of PPD.
1.4. Other Steroids during Pregnancy and after Delivery
For other steroids, such as cortisone, progesterone, testosterone, and dehydroepiandrosterone
(DHEA), research with healthy participants has indicated increased levels during the second and third
trimester and a drop hours or days after delivery [21,22,47]. However, all these studies were based on
steroids in blood or saliva, not in hair, and the pattern of results remained complex and unresolved [48].
Furthermore, Schiller et al. argued that such a heterogenous pattern of results may also be due largely
to the complex interplay of changes in reproductive hormones during pregnancy and after delivery,
along with the complex impact of such hormones and steroids on the entire biological system associated
with the occurrence (or lack) of PPD. For example, progesterone is known to regulate the synthesis,
release, and transport of neurotransmitters associated with mood regulation [49] and rapid changes in
progesterone concentrations are associated with an increased risk of PPD [48]. Next, concentrations
of the neurosteroid dehydroepiandrosterone (DHEA) were significantly lower in individuals with
MDD, while the association between DHEA concentrations and the occurrence of PPD has yet to be
determined [48].
It also appears that testosterone concentrations have not been a focus in the search for possible
biomarkers to explain the occurrence of PPD.
Next, Guintivano et al. [50] were unable to identify any differences in the plasma concentrations
of progesterone and ALLO (allogregnanolone; a neurosteroid similar to DHEA) in women with and
without PPD six weeks after delivery.
Importantly, from previous research, it has emerged that such steroids have been assessed at
different time points, with different criteria to diagnose PPD, and different methods of sampling (blood,
saliva; but not hair), making it virtually impossible to compare results across studies.
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To conclude, research on further steroids, such a cortisone, progesterone, testosterone, or DHEA,
is scarce, and results are inconsistent and based on blood and saliva samples, while data from hair
samples are currently missing.
1.5. Hypotheses of the Current Study
The following four hypotheses and two research questions were formulated. First, following
Glynn et al. [22] and Orta et al. [36], we expected that, compared to participants without PPD,
participants with PPD would show lower hair cortisol concentrations 12 weeks before delivery. Second,
following Seth et al. [13] and Serati et al. [24] we also expected that, compared to participants without
PPD, participants with PPD would also show lower hair cortisol levels 12 weeks after delivery. Third,
based on previous studies [13,21,24], we expected that levels of cortisol would remain low and
unchanged in participants with PPD from the pre- to the post-partum stage, while in participants
without PPD, we expected a drop in high cortisol concentrations at prenatal stage to low cortisol
concentrations at the postnatal stage [29,34]. Fourth, following others [35,51–53] we anticipated that,
compared to participants without PPD, participants with PPD would also report they had symptoms of
depression before pregnancy. We explored the question of whether levels of other steroids (cortisone,
testosterone, progesterone, or DHEA) either change from the pre- to postnatal stage or whether levels
of other steroids differ between participants with and without PPD. The second exploratory question
was whether any prenatal or postnatal steroid levels could predict scores on the Edinburgh postnatal
depression scale (EPDS, continuous dimension) and PPD status (yes vs. no; categorical variable).
2. Methods
2.1. Procedure
Twelve weeks after delivery, women giving birth at the Department of Obstetrics and Gynecology
of the Hamadan University of Medical Sciences (Hamadan, Iran) were approached between January
2017 and January 2019 to participate in the present cross-sectional study on the associations between
hair steroid levels and post-partum depression. Women eligible to participate were fully informed
about the aims of the study and the confidential and secure data handling. Thereafter, participants
signed a written informed consent. Experienced psychiatrists and clinical psychologists conducted a
psychiatric interview to identify participants with major depressive disorders and the specifier of onset
within four weeks after delivery and to ascertain the diagnosis of PPD, using the Mini International
Neuropsychiatric Interview [54]. Participants then completed a series of questionnaires covering
sociodemographic information, and symptoms of depression (see details below). Next, hair strands
were taken from the occipital region of the scalp (see details below) and assessed for hair steroid levels.
The ethics committee of the Hamadan University of Medical Sciences approved the study (HUMS;
Hamadan, Iran; IR.UMSHA.REC.1395.578), which was performed in accordance with the principles
laid down in the seventh and current edition (2013) of the Declaration of Helsinki.
To establish the quality of the study, we completed the checklist of the Systematic Assessment of
Quality in Observational Research (SAQOR; [55], achieving a score of 16 out of a maximum possible 17
(see Table S1).
2.2. Sample
A total of 495 women were approached 12 weeks after delivery. Inclusion criteria for participants
with PPD were as follows: 1. Age between 18 and 35 years; 2. vaginal delivery occurred 12 weeks
before; 3. willing and able to comply with the study conditions, specifically, to provide hair strands;
4. had a healthy newborn at the moment of delivery, as ascertained by an Apgar-score of eight or
higher (see Table 1); 5. minimum gestational age: 37 weeks; 6. diagnosis of post-partum depression,
as ascertained by a psychiatrist or clinical psychologist; 7. Edinburgh Postnatal Depression scale
(EPDS; see below) score of 12 points or higher; 8. Beck Depression Inventory (BDI; see below) score of
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20 points or higher; 9. signed written informed consent. Exclusion criteria were: 1. Acute suicidality;
2. comorbid psychiatric issues, such as bipolar disorder, substance use disorder, or acute psychosis.
Inclusion criteria for participants without PPD were as follows: 1 to 5 and 9 as for the PPD group;
6. Edinburgh Postnatal Depression scale (EPDS; see below) score of 5 points or lower; 7. Beck Depression
Inventory (BDI; see below) score of 10 points or lower. Exclusion criteria were the same as for the
PPD group.
Being primipara or multipara was not an inclusion or exclusion criterion.
Of the 495 women approached, 65 fulfilled the inclusion criteria for post-partum depression
(13.3% of the approached sample); of these, 48 agreed to participate in the study (73.48% of those
fulfilling the criteria of PPD), and 17 refused to participate (26.52%). Additionally, of the 495 women
approached, 41 (8.3%) did neither fulfill the criteria for participants with or without PPD, and 389
fulfilled the criteria for participants without PPD (78.43% of the approached sample); 112 refused
to participate (28.8%), and 50 participants were randomly selected from the remaining pool of 277
possible participants without PPD. Randomization occurred based on the following criteria: matching
the group of participants with PPD as regards age, gestational age, and Apgar-score 10’ after delivery.
A total of 167 participants fulfilled these criteria, and their codes were put in sealed and separate
envelopes; sealed envelopes were put in an opaque ballot box and stirred. A staff member of the
hospital not otherwise involved in the study picked out 50 envelopes.
2.3. Sample Size Calculation
Sample size calculation was performed with G*Power [56]. We anticipated a large effect size for
EPDS scores of d = 0.8 [57], an alpha of 0.05, and a Power (1-beta error probability) of 0.95. This yielded
a total sample size of 84. To counterbalance possible dropouts and withdrawals, the sample sizes were
set at 50 participants with PPD and 50 without PPD.
2.4. Tools
Self-Ratings of Symptoms of Depression
Edinburgh Postnatal Depression Scale (EPDS)
Participants completed the EPDS [58], which consists of ten items. The anchor points for each item
are 0 and 3. Higher total scores reflect more marked symptoms of postnatal depression. The maximum
score is 30, and a score of 10 or more is taken to indicate the presence of postnatal depression. However,
we employed the more restrictive cut-off score of 12 for the self-rating of post-partum depression;
others recommend to use a cut-off score of 13 [59]. For the self-identification of no PPD, we applied a
cut-off score of 5 (Cronbach’s alpha = 0.84).
Beck Depression Inventory (BDI)
Patients completed the BDI [60] (Farsi version; for psychometric properties of this version see
Ghassemzadeh et al. [61]). The questionnaire consists of 21 items and assesses different dimensions of
depressive symptomatology such as depressed mood, loss of appetite, sleep disorders, and suicidality.
Each question has a set of at least four possible responses varying in intensity; e.g., “sadness”:
0 = “I do not feel sad”; 1 = “I feel sad”; 2 = “I am sad all the time and I can’t snap out of it”; 3 = “I am
so sad or unhappy that I can’t stand it”. Higher scores reflect greater severity of depressive symptoms
(Cronbach’s alpha = 0.90).
Symptoms of Depression in the Past
Participants were asked if, in the past (that is before pregnancy), they had been diagnosed with a
major depressive disorder or if they had undergone psychological or pharmacological interventions to
treat symptoms of depression. Answer was ‘yes’ or ‘no’.
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Table 1. Descriptive and inferential statistical indices of hair steroids, separately for participants with (n = 48) and without (n = 50) postpartum depression.
Group Statistics
With PPD Healthy Controls
N 48 48 50 50
Time period
of steroid
levels
Prenatal Postnatal d Prenatal Postnatal d
Hair steroids M (SD) M (SD) M (SD) M (SD) Time Group Time × Groupinteraction
F ηp2 F ηp2 F ηp2
Cortisol 5.62 (3.98) 4.18 (2.59) 0.43 (S) 16.71 (9.51) 7.77 (5.47) 1.15 (L) 40.43 *** 0.296 (L) 10.47 *** 0.373(M) 21.08 *** 0.180 (L)
Cortisone 12.48 (7.57) 6.14 (3.50) 1.08 (L) 48.49 (26.35) 17.94 (12.83) 1.47 (L) 59.44 *** 0.282 (L) 17.97 *** 0.158 (L) 25.63 *** 0.211 (L)
Testosterone 0.34 (0.53) 0.42 (0.45) 0.16 (T) 0.58 (0.79) 0.82 (0.95) 0.27 (S) 1.00 0.010 (S) 1.52 0.016 (S) 0.79 0.008 (S)
Progesterone 30.66 (26.44) 40.58(25.37) 0.38 (S) 107.59 (45.03) 86.91 (51.55) 0.42 (S) 0.60 0.006 (S) 19.13 *** 0.166 (L) 4.80 * 0.049 (S)
DHEA 7.74 (4.56) 6.34 (5.37) 0.28 (S) 3.93 (2.97) 2.95 (2.64) 0.34 (S) 3.53 (*) 0.035 (S) 7.48 **
0.072
(M) 0.11 0.001 (S)
Notes: Values: Always nmol/L. PPD = postpartum depression; DHEA = dehydroepiandrosterone (*) = p < 0.10; * = p < 0.05; ** = p < 0.01; *** = p < 0.001; (T) = trivial effect size; (S) = small
effect size, (M) = medium effect size; (L) = large effect size. Statistics always controlling for baseline values.
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2.5. Apgar Score
The Apgar score is a quick method of summarizing a newborn’s health. The acronym stands
for A(ppearance), P(ulse), G(rimace), A(ctivity), R(espiration). The sum score ranges from 0 to 10.
Scores of 7 and higher are generally normal, scores between 4 and 6 are fairly low, and scores of 3 and
lower are critically low (psychometric properties of the Farsi/Persian version: Eslami and Falah [62].
2.6. Hair Strands Sampling
To sample hair strands, we followed the recommendations of Kirschbaum et al. [63] and
others [64–67]. The steps are as follows:
First, trained staff members divide a participant’s hair at the back of the head using a hair grip.
Second, two to three hair strands are separated close to the participants’ scalp in the posterior
vertex region. Hair strands should be at least 3 mm in diameter; as a rule of thumb, 3 mm is equal to
half of the diameter of a pencil.
Third, hair strands are combed.
Fourth, combed hair strands are bundled with a prepared packthread loop.
Fifth, 6 cm of strands are cut as close as possible to the scalp.
Sixth, strands are placed in prepared aluminum foil.
Seventh, the scalp near end with the packthread loop is clearly marked with a water-proof marker.
Eighth, the aluminum foil is folded and both ends are sealed.
Ninths, all aluminum foils are consecutively numbered and labeled.
The 6 cm of hair closest to the scalp was tested for steroid concentrations and provided a value
reflecting hair steroid concentrations for the last 2 × 12 weeks, that is to say, 12 weeks before and
12 weeks after delivery (assuming an average growth rate of 1cm/month). All participants had long
hair and could provide sufficient material for analysis. Note that 3 cm hair segments close to the scalp
correspond to a more recent period in time (postpartum), while 3 cm segments distant from the scalp
correspond to a more distant period (antepartum). Consequently, hair strands were cut in 2 × 3 cm,
corresponding to the two time periods. The two 3 cm hair strands were separately analyzed.
2.7. Assessment of Hair Steroids
Hair steroids were assessed by the biochemical Laboratory of the University of Dresden (Germany)
using mass spectrometry (LCMS/MS), as thoroughly described in Gao et al. [67] and elsewhere [64].
Samples were washed in 2.5 mL isopropanol for 3 min, and steroid hormones were extracted from
7.5 mg of whole, non-pulverized hair using 1.8 mL methanol in the presence of 50 µL cortisol-d4,
cortisone-d7, testosterone-d5, DHEA-d4, and progesterone-d9 as internal standards for 18 h at room
temperature. Samples were spun in a bench top centrifuge (Mikro 22R; Hettich GmbH and Co. KG,
Tuttlingen, Germany) at 15.200 g relative centrifugal force for 2 min, and 1 mL of the clear supernatant
was transferred into a new 2 mL tube. The alcohol was evaporated at 50 ◦C under a constant stream of
nitrogen and reconstituted with 225 µL double-distilled water, 50 µL of which were injected into a
Shimadzu HPLC-tandem mass spectrometry system (Shimadzu, Canby, OR, USA) coupled to an AB
Sciex API 5000 Turbo-ion-spray triple quadrupole tandem mass spectrometer (AB Sciex, Foster City, CA,
USA) with purification by online solid-phase extraction. The lower limits of quantification (LOQ) of
this analysis were below 0.1 pg/mg for cortisol and cortisone; for testosterone, DHEA and progesterone
the LOQ were below or equal to 1 pg/mL. The inter- and intraassay coefficients of variance were
below 10%, for progesterone, DHEA, and for testosterone the CV% were below 15%. We refer to the
publication of Gao et al. [67] for those readers wanting more specific chemical and pharmacological
details of the analyses.
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2.8. Statistical Analysis
To detect possible confounders, preliminary computations were performed. Specifically, a series of
Pearson’s correlations was computed between maternal age, gestational age, Apgar scores, symptoms
depression, and PPD, and hair steroids. All correlation coefficients were < 0.12, (ps > 0.30); accordingly,
maternal age, gestational age, and Apgar scores were not introduced as possible confounders.
Next, to compare sociodemographic and depression-related dimensions between participants
with and without PPD, a series of t-tests was performed with Group (with and without PPD) as factor
and age, gestational age, symptoms of depression (Beck Depression Inventory; Edinburgh Postnatal
Depression Scale), and infants’ Apgar scores as independent dimensions.
In the next step, we examined whether hair steroid concentrations changed over time and between
participants with or without PPD. To this end, a series of MANOVAs for repeated measures was
computed with the factors Group (with vs. without PPD), Time (pre- vs. post-natal), and the Group
by Time-interactions, and hair steroids (cortisol, cortisone, testosterone, progesterone, and DHEA)
as dependent variables, always controlling for baseline values, as these values did descriptively
differ between the two groups. For F-tests, effect sizes were reported with partial eta-squared (ηp2),
with ηp2 ≤ 0.019, indicating trivial effect sizes, 0.020 ≤ ηp2 ≤ 0.059 indicating small, 0.06 ≤ ηp2 ≤ 0.139
indicating medium, and 0.14 ≤ ηp2, indicating large effect sizes [68]. For t-tests, effect sizes were
reported with Cohen’s d, where effect sizes were evaluated as trivial (ds: 0–0.19), small (ds: 0.20–0.49),
medium (ds: 0.50–0.79), or large (ds: 0.80 and greater) [68].
Pearson’s correlations were computed for associations between symptoms of depression and
hair steroids.
A Chi-square test was computed to determine whether participants with PPD were more likely
than participants without PPD to report issues of depression before pregnancy. We ran an odds-ratio
to calculate the risk to be assigned to the group of participants with PPD, if issues of depression were
also present before pregnancy.
In a further step, to predict post-partum depression scores (Edinburgh Postnatal Depression Scale)
as a function of prenatal hair steroid levels, a multiple regression analysis was performed.
In a last step, to predict the PPD status (yes vs. no) as a function of pre- and post-natal hair steroid
levels, a binary logistic regression analysis was performed.
The nominal level of significance was set at alpha < 0.05. All statistical computations were
performed with SPSS® 25.0 (IBM Corporation, Armonk, NY, USA) for Apple® Mac®.
3. Results
Generally, descriptive and inferential statistical indices are reported in tables and not repeated in
the body of the text.
3.1. Sample Characteristics
Table 2 reports the sample characteristics of participants with (n = 48) and without (n= 50)
post-partum depression. A total of 90 out of 98 were primiparae. Eight participants had given birth for
a second time.
Participants with and without PPD did not differ with respect to age, gestational age, or infants’
Apgar scores 10 min following delivery. Compared to participants without PPD, participants with
PPD had higher depression scores (BDI; EPDS), and immediately after delivery their infants had a
lower Apgar score. Additionally, participants with PPD significantly more often had a history of a
previous depressive episode.
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Table 2. Descriptive and inferential statistical indices of sociodemographic, depression- and
delivery-related information, separately for participants with post-partum depression (PPD) (N = 48),
and without post-partum depression (N = 50).
Groups Statistics
Individuals
with PPD
Individuals
without PPD
N 48 50
n (%) n (%) X2-test
Depressive episode in life (yes/no) 21/27 1/49 X2 (N = 98, df = 1) = 24.52 ***
M (SD) M (SD) t-tests Cohen’s d
Age (years) 25.88 (4.28) 25.22 (4.88) t(96) = 0.71 0.14 (S)
Beck Depression Inventory 28.08 (9.19) 4.30 (3.13) t(96) = 17.28 *** 3.49 (L)
Edinburgh Postnatal Depression Scale 15.69 (3.47) 3.82 (2.76) t(96) = 18.77 *** 3.78 (L)
Gestational age (days) 270.23 (12.79) 274.04 (11.92) t(96) = 1.53 0.00 (-)
Apgar score at delivery 8.81 (0.70) 9.98 (0.25) t(96) = 1.58 2.23 (L)
Apgar score 10′ after delivery 9.85 (0.50) 9.96 (0.20) t(96) = 1.38 0.29 (S)
Notes *** = p < 0.001. (S) = small effect: t size; (M) = medium effect size; (L) = large effect size.
3.2. Hair Steroids, Separately for Participants with (n = 48) and without (n = 50) Post-Partum Depression,
and Separately for Prenatal and Postnatal Hair Segments
Table 1 provides the descriptive and inferential statistical overview of hair steroid values, both
prenatal and postnatal, and separately for participants with and without PPD.
Cortisol levels decreased significantly from the pre- to postnatal stage, but more so in participants
without PPD. Participants with PPD had lower cortisol levels than those without. As shown in Figure 1,
cortisol levels remained unchanged and low in participants with PPD from prenatal to postnatal stage
(small effect size), while in participants without PPD, cortisol levels dropped from prenatal to postnatal
stage (large effect size).J. Clin. Med. 2019, 8, x FOR PEER REVIEW 11 of 21 
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Cortisone levels also decreased significantly from pre- to postnatal stage, but more so in participants
without PPD (though always large effect sizes within groups). Participants with PPD had lower
cortisone levels that those without.
Testosterone levels neither changed significantly over time nor differed between pre- and postnatal
stages (trivial or small effect sizes within groups).
Progesterone levels decreased in participants without PPD but increased in individuals with PPD
(though always small effect sizes within groups). Compared to those with PPD, participants without
PPD had higher progesterone levels.
DHEA levels decreased from the pre- to postnatal stages (always small effect sizes within groups).
Participants with PPD had higher DHEA levels than participants without PPD.
3.3. Correlations between Symptoms of Depression and Steroid Levels (Prenatal and Postnatal Stage)
Table 3 reports the Pearson’s correlation coefficients between symptoms of depression (BDI, EPDS)
and steroid levels (entire sample). Please see Table 3 for all the details. Here, we summarize the most
important correlations.
Higher depression scores (BDI) were associated with lower prenatal cortisol, lower pre- and
postnatal cortisone, lower progesterone (pre- and postnatal), and higher DHEA (pre- and postnatal).
Higher post-partum depression scores (EPDS) were associated with lower prenatal cortisol,
lower cortisone (pre- and postnatal), lower progesterone (pre- and postnatal), and higher DHEA
(pre- and postnatal).
Prenatal cortisol was associated with postnatal cortisol, and pre- and postnatal cortisone.
Prenatal cortisol did not correlate with testosterone, progesterone, or DHEA.
Postnatal testosterone did not correlate with other steroids.
Higher prenatal progesterone was associated with higher postnatal progesterone.
Higher prenatal DHEA was associated with higher postnatal DHEA.
To summarize, more marked symptoms of depression were associated with lower cortisol,
cortisone, and progesterone levels, both at the pre- and postnatal stages, and with higher DHEA levels,
both at the pre- and postnatal stages. Cortisol levels were associated with cortisone levels. Testosterone
was generally unrelated, except for higher prenatal progesterone levels.
3.4. Current Post-Partum Depression and Issues of Depression before Pregnancy
Participants with current PPD reported having had issues of depression before pregnancy
(X2(N = 98, df = 1) = 24.52, p = 0.001). The odds of suffering currently from PPD was 38.11-fold higher
in participants with issues of depression before pregnancy, compared to participants without issues of
depression before pregnancy (OR = 38.11; CI (95%): 4.86–299.13).
3.5. Predicting Postnatal Depression Levels (Edinburgh Depression Rating Scale) Based on Prenatal
Hair Steroids
A multiple regression analysis was performed to predict levels of postnatal depression
(Edinburgh Depression Rating Scale) as a function of prenatal hair steroid levels. First,
the Durban-Watson coefficient was satisfactory, and second, predictors explained 30% (R2 = 0.30) of
the variance in postpartum depression.
As shown in Table 4, both lower prenatal cortisone and progesterone levels predicted postpartum
depression levels, while prenatal cortisol, testosterone, and DHEA did not reach statistical significance.
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Table 3. Correlations between symptoms of depression and hair steroids (N = 98).
Dimensions
1 2 3 4 5 6 7 8 9 10 11 12
1 BDI - 0.90 *** −0.28 ** −0.13 −0.36 *** −0.23 * −0.14 −0.08 −0.40 *** −0.23 * 0.21 * 0.21 *
2 EPDS - −0.23 ** −0.15 −0.35 ** −0.24 * −0.16 −0.14 −0.40 *** −0.22 * 0.19 (*) 0.20 *
3 Cortisol pre - 0.91 *** 0.94 *** 0.86 *** −0.12 −0.04 0.04 −0.02 0.07 0.11
4 Cortisol post - 0.86 *** 0.04 *** −0.09 −0.03 −0.01 −0.03 0.07 0.17
5 Cortisone pre - 0.91 *** −0.15 −0.07 0.03 −0.03 0.00 0.09
6 Cortisone post - −0.11 −0.08 −0.02 −0.03 0.00 0.11
7 Testosterone pre - 0.90 *** 0.61 *** 0.22 * 0.01 0.00
8 Testosterone post - 0.05 −0.05 −0.04 −0.02
9 Progesterone pre - 0.65 *** −0.16 −0.14
10 Progesterone post - −0.15 −0.10
11 DHEA pre - 0.65 **
12 DHEA post -
Notes: BDI = Beck Depression Inventory; EPDS = Edinburgh Postpartum Depression Scale; DHEA = dehydroepiandrosterone; (*) = p < 0.10; * = p < 0.05; ** = p < 0.01; *** = p < 0.001.
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Table 4. Multiple linear regression with post-partum depression scores as dependent variables
(Edinburgh Postnatal Depression Scale) and antenatal hair steroid levels (cortisol; cortisone; testosterone;
progesterone; DHEA) as predictors.
Dimension Variables Coefficient StandardError
Coefficient
β
t p R R2
Durbin-Watson
Coefficient
Edinburgh Postnatal
Depression Scale Intercept 12.69 1.038 - 12.22 0.001 0.552 0.30 1.78
Antenatal
cortisol 0.152 0.111 0.127 1.373 0.173
Antenatal
cortisone −0.105 0.041 −0.664 −2.548 0.012
Antenatal
testosterone 0.219 1.112 0.022 0.197 0.884
Antenatal
progesterone −0.032 0.009 −0.393 −3.453 0.001
Antenatal
DHEA 0.099 0.085 0.1.06 1.164 0.248
Notes: DHEA = dehydroepiandrosterone.
3.6. Predicting Postnatal Depression Status on the Basis of Prenatal and Postnatal Hair Steroid Levels
A binary logistic regression analysis was performed to predict the postnatal depression status
(yes vs. no) based on both prenatal and postnatal hair steroid levels. Compared to the default model,
which correctly assigned 51% of participants as being depressed or not, the new model assigned 98%
of participants correctly as being depressed or not. Predictors explained 92.4% of the variance in the
dependent variable (Nagelkerke R2: 0.924). These predictors were as follows (as shown in Table 5):
A participant was correctly assigned as postnatally depressed if prenatally lower levels of cortisol and
progesterone, and higher levels of DHEA, were observed, and if postnatally lower levels of cortisol,
cortisone, progesterone, and higher levels of DHEA were observed.
Table 5. Binary logistic regression with post-partum depression (yes vs. no) as dependent variable,
and antenatal hair steroid levels (cortisol; cortisone; testosterone; progesterone; DHEA) as predictors.
Dimension Variables Coefficient StandardError Wald p Nagelkerke R
2
Depression
(yes vs. no) Intercept 2.99 1.074 7.729 0.003 0.924
Cortisol prenatal −0.526 0.150 12.366 0.000
Cortisol postnatal 1.083 0.307 12.471 0.001
Cortisone postnatal −0.304 0.131 5.440 0.020
Progesterone prenatal −0.019 0.007 7.043 0.008
Progesterone postnatal −0.024 0.011 4.759 0.029
DHEA prenatal 0.211 0.099 4.525 0.033
Excluded
variables
Cortisone prenatal, testosterone prenatal, testosterone postnatal, DHEA postnatal,
(all Wald’s < 1.8, all p’s > 0.10).
Notes: DHEA = dehydroepiandrosterone.
4. Discussion
The key findings of the present study were that, compared to women without post-partum
depression (PPD), women with PPD had lower hair cortisol, cortisone, and progesterone levels
and higher DHEA levels, both pre- and postnatally. Lower prenatal cortisone and progesterone
levels predicted higher post-partum depression levels (continuous dimension). Prenatal low cortisol,
cortisone, and progesterone, and higher DHEA levels, together with postnatal low cortisol, cortisone,
and progesterone, and higher DHEA levels predicted status as participants with post-partum depression
with an accuracy of 98%. Last, testosterone levels were unrelated to PPD. The present results add to
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the current literature in an important and new way, as specific combinations of hair steroids both pre-
and postnatally were associated with PPD scores and PPD status 12 weeks after delivery.
Four hypotheses and two research questions were formulated, and each of these will now
be considered.
Our first hypothesis was that, compared to healthy controls, women with PPD would release less
cortisol, prenatally, and this was confirmed. The present findings, therefore, support the concept of
hypocortisolemia, which appears to mirror a down-regulated (and, therefore, dysfunctional) HPA
AA in women with PPD [11,21,22]. Importantly, this down-regulation was already present prenatally.
In contrast, the present pattern of result is at odds with the studies that failed to find an association
between lower cortisol levels and post-partum depression (see overview in [13,24,33]). The present
findings are also at odds with the studies reporting increased hair cortisol concentrations in women
with PPD [34]. While we accept that methodological issues (sample size, cortisol sampling, definition of
PPD) might have led to previous contradictory findings, the present study was statistically robust
and fulfilled all the quality criteria for a methodologically sound study (see Table S1). Accordingly,
the present results expand upon previous results in showing that hypocortisolemia was present at
least 12 weeks before delivery in women with PPD.
Our second hypothesis was that, compared to the healthy controls, women with PPD would
also release less cortisol postnatally, and this was also confirmed. The present findings, therefore,
support the notion of hypocortisolemia.
Our third hypothesis was that levels of cortisol would remain unaltered and low in participants
with PPD, while we expected a drop in cortisol levels from a prenatal high to postnatal low levels
in healthy participants. Again, these expectations were fully confirmed (see Table 3 and Figure 1).
The findings are, therefore, entirely in agreement with the notion of pregnancy as a transient and
physiological period of hypercortisolism [69]. Among healthy pregnant women, cortisol secretion
increases exponentially from the second to the third trimester [34] as a result of the placenta’s activity
as an additional endocrine organ. Specifically, the placenta releases additional CRH into both the
mother’s and fetus’s blood supply and triggers further cortisol release, which is not downregulated
by the mineralocorticoid-receptor and glucocorticoid-receptor feedback loop [22,29]. At a behavioral
level, a pregnant woman with a well-functioning stress response becomes less responsive to external
stressors. In contrast, pregnant women with down-regulated HPA AA mirroring hypocortisolemia do
not appear to be able to react adequately to external stressors, resulting in possible social withdrawal,
reduced activity, and a depressed mood. Taken together, therefore, the present findings strongly
suggest that it is inappropriate to assume that low cortisol secretion equates to positive psychological
functioning and that high cortisol secretion indicates psychological issues [16].
Our fourth hypothesis was that participants currently suffering from PPD would also report that
they had issues of depression in their past and before pregnancy. This prediction was confirmed.
Participants with issues of depression before pregnancy had a 38.1-fold risk of suffering from PPD
currently. Our findings support the proposition that PPD can be considered an additional expression
of depression among women with general issues of depression [51–53,70]. In this respect, the present
findings are in accord with those studies concluding that there are both biological and psychosocial
predictors of PPD. Specifically, the strongest biological predictors are the dysregulation of the HPA AA,
along with inflammatory processes and genetic vulnerabilities [12], while the strongest psychological
predictors are severe life events, symptoms of depression before pregnancy [12], certain forms of
chronic strain, low relationship quality, and low support from partner and mother [12,70].
Our first exploratory research question concerned whether other steroids (cortisone, testosterone,
progesterone, DHEA) differed in level between the pre- and postnatal stages or between participants
with and without PPD.
As reported in Table 3, testosterone differed neither between participants with and without PPD,
nor from the pre- to the postnatal stage. Following Schiller et al. [48], testosterone concentrations have
not been a focus of research looking for PPD-related biomarkers, and the results of the present study
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suggest that testosterone concentrations do not contribute to an endcrinological explanation of the
occurrence of PPD.
Cortisone levels changed from the pre- to the post-natal stage, as did cortisol levels. While there
is no direct evidence in the literature for such changes in cortisone concentrations in women with a
higher risk of PPD, we assume that cortisol and cortisone concentrations go in parallel, as oxidation of
cortisol leads to its inactive form, cortisone.
DHEA levels were higher in participants with PPD and declined over time. This result appears to
be at odds with the observation that DHEA concentrations are lower among individuals with major
depressive disorders [48]. However, Schiller et al. [48] also noted that associations between DHEA
concentrations and the occurrence of PPD have not so far been shown. It follows that the present
results appear to be the very first on the topic (and, above all, based on hair steroid analyses), and that
further studies are needed to replicate the present findings.
For progesterone, this increased over time in participants with PPD, while it decreased in healthy
participants. Again, to the best of our knowledge, this is the first study to investigate these hair
steroids both pre- and postnatally and between participants, respectively, with and without PPD. Thus,
the present findings might be used as a point of reference for future studies.
For the second exploratory research question, the combination of hair steroid levels both pre- and
postnatally allowed us to predict with 98% accuracy a diagnosis of PPD. As shown in Tables 4 and 5,
in addition to pre- and postnatal low cortisol and low cortisone, pre- and postnatal low progesterone
and high DHEA levels predicted the PPD status. It follows that the combination of several hair steroids
both pre- and postnatally, rather than a single biomarker, allow accurate prediction of PPD 12 weeks
after delivery.
Despite the novelty of these findings, the following limitations caution against their
overgeneralization. First, in addition to a thorough clinical and psychiatric interview to ascertain
the diagnosis of major depressive disorders, with the specifier of onset four weeks after delivery to
establish the existence of post-partum depression, we employed the Edinburgh Postnatal Depression
Scale, the most commonly used screening instrument to self-rate symptoms of PPD. The EPDS has
some limitations. Its predictive power with respect to PPD is just 47%–64%, with a risk, therefore, of a
substantial proportion of false positives [71]. However, to counter this, we used a cut-off score of 12
instead of 10 to assign participants to the PPD condition, and a score of 5 or lower for assignment
to the healthy condition. As shown in Tables 4 and 5, the wisdom of this choice of cut-off values
was confirmed by hair steroid levels. Second, Hagen [72] noted that factors increasing the risk of
PPD include, for example, poor quality of marital relations and demanding or challenging infant
behavior. We did not check for such factors, and it is, therefore, possible that other unassessed and
latent variables might have biased two or more dimensions in the same or opposite directions. Third,
participants were asked if they had experienced symptoms of depression during their lifetimes and
before pregnancy. Asking about symptoms of depression during the pregnancy might have provided
further insights into the associations between the current psychological status during pregnancy
and ante- and postnatal hair steroids concentrations. Fourth, from the perspective of evolutionary
psychology, PPD is an adaptive strategy to save energy, to signal non-hostility, and to trigger receipt of
resources from the social environment to help both needy mother and newborn. It would, therefore,
have been useful to know whether or how the PPD status of the mother altered her relationship with
her husband and other family members. Fifth, we assessed steroids in the hair, which, by definition,
are not comparable to steroids in blood, urine, or saliva. We assessed steroids in hair using mass
spectrometry, while in other studies blood, saliva, or urine cortisol concentrations were assessed with
ELISA kits. It follows that comparisons of results between studies using different assessment tools with
varying sensitivities and steroid concentrations, along with different samples and diagnostic criteria,
might be problematic. Furthermore, as discussed extensively by Stalder et al. [19], hair steroid levels
may vary as a function of season, sweating, and other confounding factors. Sixth, we assessed hair
steroids of the last trimester and the first 12 weeks after delivery. Accordingly, the present results do
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not reflect steroid concentrations for all trimesters, and the results do not tell us more about hair steroid
concentrations since the very beginning of pregnancy. However, this would have been particularly
interesting. As reported in the present data, and as mentioned in elsewhere [51,52], women with
post-partum depression already have a higher risk of reporting symptoms of depression before
pregnancy. Accordingly, assessing hair steroids throughout pregnancy or even before pregnancy would
have yielded a more comprehensive understanding of the underlying neuroendocrinological processes
preceding PPD. Seventh, we assessed a small sample of women with and without PPD. Accordingly,
the present results, particularly the exploratory ones, require replication with larger samples.
Clinical Implications
The pattern of results suggests that the combination of symptoms of depression before pregnancy
and low hair steroid concentrations at least 12 weeks before delivery could be employed to estimate the
risk of the future mother suffering from symptoms of post-partum depression 12 weeks after delivery.
Accordingly, pregnant women at risk might receive specific counseling and psychological support to
prevent or to reduce the risk of PPD. This pattern of results further implies that we are highly unlikely
to find one single biomarker to predict PPD. Rather, the combination of several hair steroids and the
occurrence of symptoms of depression before pregnancy appears more promising.
5. Conclusions
The present data confirmed the notion that hypocortisolemia in women with post-partum
depression lasts at least from the last 12 weeks before delivery to at least the following 12 weeks
after delivery. Furthermore, pre- and postnatal hair steroid levels of cortisol, cortisone, progesterone,
and DHEA, but not testosterone, showed different patterns in women with and without PPD.
The combination of cortisol, cortisone, progesterone, and DHEA allowed precise prediction of a
women’s status with respect to PPD.
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